Zachary C Dobbin

Zachary C Dobbin

UNVERIFIED PROFILE

Are you Zachary C Dobbin?   Register this Author

Register author
Zachary C Dobbin

Zachary C Dobbin

Publications by authors named "Zachary C Dobbin"

Are you Zachary C Dobbin?   Register this Author

14Publications

302Reads

46Profile Views

Ovarian and cervical cancer patient derived xenografts: The past, present, and future.

Gynecol Oncol 2015 Aug 27;138(2):486-91. Epub 2015 May 27.

Department of Radiation Oncology, University of Alabama at Birmingham, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2015.05.022DOI Listing
August 2015

Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer.

Obstet Gynecol 2014 Nov;124(5):881-5

Departments of Obstetrics and Gynecology and Pathology, University of Alabama at Birmingham, Birmingham, Alabama; the Ludwig Center of Cancer Genetics and Therapeutics and the Swim Across America Laboratory at Johns Hopkins University, Baltimore, Maryland; and the Departments of Obstetrics and Gynecology and Pathology, University of Virginia, Charlottesville, Virginia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/AOG.0000000000000484DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316672PMC
November 2014

An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer.

Gynecol Oncol 2014 Aug 15;134(2):331-7. Epub 2014 May 15.

Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2014.05.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221419PMC
August 2014

Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer.

Oncotarget 2014 Aug;5(16):7065-80

Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA. These authors contributed equally to this work.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196184PMC
http://dx.doi.org/10.18632/oncotarget.2295DOI Listing
August 2014

Isolation and characterization of potential cancer stem cells from solid human tumors--potential applications.

Curr Protoc Pharmacol 2013 Dec 2;63:Unit 14.28.. Epub 2013 Dec 2.

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, Alabama.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/0471141755.ph1428s63
Publisher Site
http://dx.doi.org/10.1002/0471141755.ph1428s63DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041697PMC
December 2013

The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer.

Int J Mol Sci 2013 Apr 15;14(4):8213-27. Epub 2013 Apr 15.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Wallace Tumor Institute, 1824 6th Avenue South, Birmingham, AL 35233, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms14048213DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645739PMC
April 2013

Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.

Clin Cancer Res 2013 Jan 12;19(1):170-82. Epub 2012 Nov 12.

Departments of Obstetrics and Gynecology, Radiation Oncology, and Pathology, University of Alabama at Birmingham, Birmingham, AL 35249, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-1045DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3537868PMC
January 2013

SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK.

Mol Cancer Res 2012 Nov 10;10(11):1462-72. Epub 2012 Sep 10.

Gene Expression and Regulation Program, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-12-0335DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501543PMC
November 2012

Smoothened antagonists reverse taxane resistance in ovarian cancer.

Mol Cancer Ther 2012 Jul 2;11(7):1587-97. Epub 2012 May 2.

Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-11-1058DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392529PMC
July 2012

Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK).

J Biol Chem 2012 May 20;287(21):17682-92. Epub 2012 Mar 20.

Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M111.304022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366801PMC
May 2012

Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.

Clin Cancer Res 2012 Feb 5;18(3):869-81. Epub 2011 Dec 5.

Department of Obstetrics, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-2188DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3271164PMC
February 2012